Here is the design of a clinical trial:

Official Title: Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Included conditions:
- Newly Diagnosed Oligometastatic Prostate Cancer

Study Armgroups:
- {'label': 'Experimental Arm', 'type': 'EXPERIMENTAL', 'description': 'Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.', 'interventionNames': ['Procedure: radical prostatectomy', 'Radiation: stereotactic body radiotherapy', 'Drug: Leuprolide', 'Drug: apalutamide', 'Drug: abiraterone']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'radical prostatectomy', 'description': 'surgical removal of the prostate', 'armGroupLabels': ['Experimental Arm']}
- {'type': 'RADIATION', 'name': 'stereotactic body radiotherapy', 'description': 'Highly targeted radiation', 'armGroupLabels': ['Experimental Arm'], 'otherNames': ['SBRT']}
- {'type': 'DRUG', 'name': 'Leuprolide', 'description': 'Lowers serum testosterone', 'armGroupLabels': ['Experimental Arm'], 'otherNames': ['ADT']}
- {'type': 'DRUG', 'name': 'apalutamide', 'description': 'antiandrogen', 'armGroupLabels': ['Experimental Arm'], 'otherNames': ['ARN-509']}
- {'type': 'DRUG', 'name': 'abiraterone', 'description': 'Inhibits androgen synthesis', 'armGroupLabels': ['Experimental Arm'], 'otherNames': ['zytiga']}

Primary Outcomes:
- {'measure': 'PSA<0.05ng/mL (radical prostatectomy) or PSA <nadir+2ng/mL (prostate radiation)', 'description': 'PSA is a biomarker for disease burden in prostate adenocarcinoma and offers a non-invasive and sensitive assessment of disease control after treatment in the vast majority of patients.', 'timeFrame': '6 months after recovery of testosterone'}

Please estimate the sample size based on the assumption: 
80% power, null hypothesis response rate of 5.5%, two-sided alternative response rate of 20%, significance level (alpha) of 0.1, 10% dropout rate.
Sample size
          The current study hypothesis is that 20% of patients will achieve a PSA <â0.05âng/mL six months after recovery of testosterone to >â150âng/dL. A sample size of Nâ=â25 evaluable patients has an 80% power to test the null hypothesis response rate of 5.5% against a two sided alternative response rate of 20% at a significance level (alpha) of 0.1. Assuming 10% of patients may not recover testosterone to â¥150âng/dL, total study Nâ=â28.